scholarly journals The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies

PLoS ONE ◽  
2018 ◽  
Vol 13 (1) ◽  
pp. e0191972 ◽  
Author(s):  
Hui Luo ◽  
Xiaohui Xu ◽  
Miaomiao Ye ◽  
Bo Sheng ◽  
Xueqiong Zhu
Keyword(s):  
Ovarian Cancer ◽  
Observational Studies ◽  
Prognostic Value ◽  
Meta Analysis

scholarly journals Prognostic Value of Serum Magnesium in Mortality Risk among Patients on Hemodialysis: A Meta-Analysis of Observational Studies

2020 ◽  
pp. 1-10
Author(s):  
Hongwei Wu ◽  
Qiang Li ◽  
Lijing Fan ◽  
Dewang Zeng ◽  
Xianggeng Chi ◽  
...  
Keyword(s):  
Mortality Risk ◽  
Cardiovascular Mortality ◽  
Observational Studies ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Serum Magnesium ◽  
Cochrane Library ◽  
Lower Serum ◽  
All Cause Mortality ◽  
End Stage

<b><i>Background:</i></b> Previous studies have reported that serum magnesium (Mg) deficiency is involved in the development of heart failure, particularly in patients with end-stage kidney disease. The association between serum Mg levels and mortality risk in patients receiving hemodialysis is controversial. We aimed to estimate the prognostic value of serum Mg concentration on all-cause mortality and cardiovascular mortality in patients receiving hemodialysis. <b><i>Methods:</i></b> We did a systematic literature search in PubMed, EMBASE, Cochrane Library, and Web of Science to identify eligible studies that reported the prognostic value of serum Mg levels in mortality risk among patients on hemodialysis. We performed a meta-analysis by pooling and analyzing hazard ratios (HRs) and 95% confidence intervals (CIs). <b><i>Results:</i></b> We identified 13 observational studies with an overall sample of 42,967 hemodialysis patients. Higher all-cause mortality (adjusted HR 1.58 [95% CI: 1.31–1.91]) and higher cardiovascular mortality (adjusted HR 3.08 [95% CI: 1.27–7.50]) were found in patients with lower serum Mg levels after multivariable adjustment. There was marked heterogeneity (<i>I</i><sup>2</sup> = 79.6%, <i>p</i> &#x3c; 0.001) that was partly explained by differences in age stratification and study area. In addition, subgroup analysis showed that a serum Mg concentration of ≤1.1 mmol/L might be the vigilant cutoff value. <b><i>Conclusion:</i></b> A lower serum Mg level was associated with higher all-cause mortality and cardiovascular mortality in patients receiving hemodialysis.

The prognostic value and clinicopathological significance of CD44 expression in ovarian cancer: a meta-analysis

2016 ◽  
Vol 294 (5) ◽  
pp. 1019-1029 ◽  
Author(s):  
Luyang Zhao ◽  
Chenglei Gu ◽  
Ke Huang ◽  
Zhe Zhang ◽  
Mingxia Ye ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Cd44 Expression ◽  
Clinicopathological Significance

Egg consumption is associated with increased risk of ovarian cancer: Evidence from a meta-analysis of observational studies

2015 ◽  
Vol 34 (4) ◽  
pp. 635-641 ◽  
Author(s):  
Sai-tian Zeng ◽  
Liang Guo ◽  
Shi-kai Liu ◽  
Dong-hui Wang ◽  
Jie Xi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Observational Studies ◽  
Meta Analysis ◽  
Egg Consumption ◽  
Increased Risk

The Effects of Metformin on Ovarian Cancer: A Systematic Review

2013 ◽  
Vol 23 (9) ◽  
pp. 1544-1551 ◽  
Author(s):  
Piyemeth Dilokthornsakul ◽  
Nathorn Chaiyakunapruk ◽  
Wichai Termrungruanglert ◽  
Chayanin Pratoomsoot ◽  
Surasak Saokeaw ◽  
...  
Keyword(s):  
Systematic Review ◽  
Ovarian Cancer ◽  
Cancer Prevention ◽  
Observational Studies ◽  
Cancer Survival ◽  
Meta Analysis ◽  
Progression Free Survival ◽  
Survival Outcomes ◽  
Diabetic Patients ◽  
Therapeutic Effects

ObjectiveThe potential therapeutic effects of metformin on several cancers were reported. However, the evidence of the effects of metformin on ovarian cancer is still limited and inconclusive. This systematic review and meta-analysis study aims to summarize the existing evidence of the therapeutic effects of metformin on ovarian cancer.MethodsWe performed systematic searches using electronic databases including PubMed and EMBASE until December 2012. Key words included “metformin” AND (“ovarian cancer” OR “ovary tumor”). All human studies assessing the effects of metformin on ovarian cancer were eligible for inclusion. All articles were reviewed independently by 2 authors with a standardized approach for the purpose of study, study design, patient characteristics, exposure, and outcomes. The data were pooled using a random-effects model.ResultsOf 190 studies retrieved, only 3 observational studies and 1 report of 2 randomized controlled trials were included. Among those studies, 2 reported the effects of metformin on survival outcomes of ovarian cancer, whereas the other 2 reported the effects of metformin on ovarian cancer prevention. The findings of studies reporting the effects on survival outcomes indicated that metformin may prolong overall, disease-specific, and progression-free survival in ovarian cancer patients. The results of studies reporting the effects of metformin on ovarian cancer prevention were meta-analyzed. It indicated that metformin tended to decrease occurrence of ovarian cancer among diabetic patients with the pooled odds ratio of 0.57 (95% confidence interval, 0.16–1.99).ConclusionsOur findings showed the potential therapeutic effects of metformin on survival outcomes of ovarian cancer and ovarian cancer prevention. However, most of the evidence was observational studies. There is a call for further well-conducted controlled clinical trials to confirm the effects of metformin on ovarian cancer survival and ovarian cancer prevention.

Sign in / Sign up

Export Citation Format

Share Document